A number of other analysts have also weighed in on TEVA. Credit Suisse Group set a $23.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a buy rating in a report on Wednesday, April 4th. Vetr lowered shares of Teva Pharmaceutical Industries from a strong-buy rating to a buy rating and set a $21.73 target price for the company. in a report on Monday, March 12th. BTIG Research lowered shares of Teva Pharmaceutical Industries from a neutral rating to a sell rating and set a $17.00 target price for the company. in a report on Friday, February 2nd. Oppenheimer reiterated a hold rating on shares of Teva Pharmaceutical Industries in a report on Thursday, February 8th. Finally, Leerink Swann decreased their price target on shares of Teva Pharmaceutical Industries from $17.00 to $16.00 and set an underperform rating for the company in a research note on Friday, February 9th. Eleven equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $19.82.
Shares of Teva Pharmaceutical Industries stock traded up $0.11 during trading on Friday, reaching $17.82. 7,278,213 shares of the stock were exchanged, compared to its average volume of 8,136,091. The company has a current ratio of 0.86, a quick ratio of 0.58 and a debt-to-equity ratio of 1.91. The firm has a market cap of $18,008.89, a P/E ratio of 4.53, a P/E/G ratio of 1.54 and a beta of 0.67. Teva Pharmaceutical Industries has a 1 year low of $10.85 and a 1 year high of $33.82.
In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 5,050 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $19.68, for a total transaction of $99,384.00. Following the completion of the transaction, the executive vice president now owns 44,517 shares of the company’s stock, valued at $876,094.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 10,734 shares of company stock valued at $204,795 in the last ninety days. Insiders own 7.10% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Calton & Associates Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $108,000. Global Financial Private Capital LLC bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $193,000. Wetherby Asset Management Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $197,000. Sigma Planning Corp bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $214,000. Finally, Comprehensive Portfolio Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $226,000. 58.22% of the stock is owned by institutional investors.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.